A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer: A Window-of-Opportunity Study
Blood samples and three core biopsies are taken after diagnosis. Treatment with atorvastatin
at a daily dosis of 80 mg is initiated 14 days before planned surgery. Translational
research will be performed from the core biopsy and blood samples taken before surgery and
from the specimen from surgery.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor biological alterations following two weeks of neo-adjuvant statin therapy in postmenopausal breast cancer patients; to evaluate the tumor proliferation using Ki67 as proliferation marker.
After two weeks of treatment with statin therapy.
Carsten Rose, MD
University Hospital Lund
Sweden: Medical Products Agency